NCT06829823Phase 2Not yet recruiting

Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-11Estimated

Enrollment · participants20Estimated

Source updated2025-10-16Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-10-14 · 1 field changed

Primary completion date changed

− Before

~~1 May 2026~~

+ After

Nov 2026

Check registry source

Study details

Conditions studied

Non-muscle Invasive Bladder Cancer (NMIBC)

Treatments or interventions studied

N-803 and BCGDrugAlso known as BCG, N-803, Bacillus Calmette-Guérin
N-803 and GemcitabineDrugAlso known as N-803, Gemcitabine, Gemzar

Primary outcomes · main study measures

measure: Efficacy of Arms A and B at Month 3 and Month 6; description: Evaluate efficacy of experimental therapies with a) intravesical N-803 plus BCG or b) intravesical N-803 plus gemcitabine by CR rate at month 3 or month 6 (for re-inducted participants) in participants with intermediate-risk NMIBC.; timeFrame: At Month 3 and Month 6

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history